Table 3 Correlations between downregulation of NEARS and poor prognostic factors in clinical prostate tumors
From: Polycomb-mediated silencing in neuroendocrine prostate cancer
Clinical parameters associated with NEARS | ||||||
|---|---|---|---|---|---|---|
Analysis | Concept | Dataset | Odds ratio | P value | Percentile | Samples |
1° vs Met | Metastasis | Lapointe Prostate | 2.4 | 1.3E-04 | Top 10% | 71 |
Metastasis | LaTulippe Prostate | 2.4 | 4.5E-04 | Top 10% | 32 | |
Metastasis | Yu Prostate | 3.5 | 2.0E-07 | Top 10% | 88 | |
Metastasis | Grasso Prostate | 3.8 | 5.6E-13 | Top 10% | 94 | |
Metastasis | Vanaja Prostate | 4.6 | 8.4E-18 | Top 10% | 32 | |
Metastasis | Taylor Prostate 3 | 6.0 | 2.0E-26 | Top 10% | 150 | |
Grade | Advanced Gleason Score | Wallace Prostate | 2.2 | 3.4E-04 | Top 10% | 65 |
Advanced Gleason Score | Vanaja Prostate | 2.4 | 6.6E-06 | Top 10% | 27 | |
Advanced Gleason Score | Lapointe Prostate | 3.4 | 1.8E-05 | Top 5% | 61 | |
Advanced Gleason Score | Tomlins Prostate | 3.6 | 1.9E-08 | Top 10% | 30 | |
Advanced Gleason Score | Taylor Prostate 3 | 3.6 | 4.4E-08 | Top 5% | 130 | |
Advanced Gleason Score | Yu Prostate | 4.4 | 4.1E-07 | Top 5% | 61 | |
Advanced Gleason Score | Setlur Prostate | 7.6 | 2.8E-04 | Top 1% | 353 | |
High Grade | Bittner Prostate | 2.5 | 3.3E-04 | Top 5% | 46 | |
Outcome | Dead at 3 years | Setlur Prostate | 2.4 | 2.0E-03 | Top 10% | 358 |
Recurrence at 5 years | Taylor Prostate 3 | 3.1 | 1.3E-09 | Top 10% | 61 | |
Recurrence at 3 years | Taylor Prostate 3 | 3.5 | 1.0E-11 | Top 10% | 107 | |
Recurrence at 5 years | Nakagwa Prostate | 10.1 | 1.0E-03 | Top 10% | 592 | |
Dead at 5 years | Setlur Prostate | 10.7 | 2.9E-06 | Top 1% | 363 | |
Recurrence at 3 years | Nakagwa Prostate | 15.2 | 7.9E-04 | Top 5% | 594 | |